Biochemically stabilized HIV-1 ENV trimer vaccine
Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.
1. An immunogenic composition comprising:
an isolated, antigenic, stabilized trimer of gp140, wherein the trimer comprises three identical polypeptide sequences, each polypeptide sequence comprising a gp140 polypeptide sequence that is at least 98% identical to residues 30-708 of SEQ ID NO: 2 and includes SEQ ID NO: 8, and further comprising a T4 fibritin trimerization domain, wherein the immunogenic composition elicits production of neutralizing antisera against HIV after injection into a subject.
2. The immunogenic composition of claim 1 , wherein the immunogenic composition elicits neutralizing antisera against HIV-1 clade C after injection into the subject.
3. An immunogenic composition including a stabilized trimer comprising:
an isolated gp140 polypeptide comprising an amino acid sequence at least 98% identical to the entire length of residues 30-708 of SEQ. ID NO: 2, wherein said amino acid sequence at least 98% identical to the entire length of residues 30-708 of SEQ. ID NO: 2 further comprises SEQ ID NO: 8, wherein said gp140 polypeptide further comprises an oligomerization domain, wherein the immunogenic composition elicits production of neutralizing antisera against HIV after injection into a subject.
4. An isolated, antigenic, stabilized trimer of gp140, comprising: a gp140 polypeptide comprising an amino acid sequence at least 98% identical to a polypeptide comprising residues 30-708 of SEQ ID NO: 2, wherein said amino acid sequence comprises an oligomerization domain, wherein the antigenic, stabilized trimer elicits production of neutralizing antisera against HIV after injection into a subject.
5. The immunogenic composition of claim 3 , wherein said oligomerization domain is a T4 fibritin trimerization domain.
6. The isolated, antigenic, stabilized trimer of gp140 of claim 4 , wherein said oligomerization domain is a T4 fibritin trimerization domain.
7. The immunogenic composition of claim 3 , wherein said amino acid sequence at least 98% identical to the entire length of residues 30-708 of SEQ ID NO; 2 further comprises SEQ in NO: 6.
8. The isolated, antigenic, stabilized trimer of gp140 of claim 4 , wherein the gp140 polypeptide comprising an amino acid sequence at least 98% identical to a polypeptide comprising residues 30-708 of SEQ ID NO: 2 further comprises SEQ ID NO: 8.
9. The isolated, antigenic, stabilized trimer of gp140 of claim 8 , wherein the gp140 polypeptide comprising an amino acid sequence at least 98% identical to a polypeptide comprising residues 30-708 of SEQ ID NO: 2 further comprises SEQ ID NO: 6.
10. The immunogenic composition of claim 1 , wherein the gp140 polypeptide sequence that is at least 98% identical to residues 30-708 of SEQ ID NO: 2 and includes SEQ ID NO: 8 also includes SEQ ID NO: 6.
11. A method of therapeutically treating a subject infected with HI comprising: contacting a subject infected with HIV with the immunogenic composition of claim 1 ; and producing neutralizing anti-HIV antisera in the subject to therapeutically treat the subject.
12. The method of claim 11 , wherein the anti-HIV antisera neutralizes HIV-1 selected from one or more of clade A, clade B and clade C.
13. The method of claim 11 , wherein HIV titer in the subject infected with HV is decreased after contacting the subject with the isolated polypeptide.
14. The method of claim 11 , wherein the HIV is HIV-1.
15. A method of inhibiting an HIV-mediated activity in a subject in need thereof comprising: contacting an HIV-infected subject with the immunogenic composition of claim 1 : and producing neutralizing anti-HIV antisera in the subject to inhibit the HIV-mediated activity.
16. The method of claim 15 , wherein the HIV-mediated activity is viral spread.
17. The method of claim 15 , wherein HIV titer in the HIV-infected subject is decreased after contacting the subject with the isolated polypeptide.
18. A method of inducing an immune response in a subject, the method comprising administering the immunogenic composition of claim 1 .